• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Effects of peptides derived from terminal modifications of the aβ central hydrophobic core on aβ fibrillization.β 淀粉样肽末端修饰对β 淀粉样肽纤维形成的影响。
ACS Chem Neurosci. 2010 Oct 20;1(10):661-78. doi: 10.1021/cn900019r. Epub 2010 Aug 26.
2
Structure-activity relationships in peptide modulators of β-amyloid protein aggregation: variation in α,α-disubstitution results in altered aggregate size and morphology.β-淀粉样蛋白聚集肽调节剂的构效关系:α,α-二取代的变化导致聚集物的大小和形态发生改变。
ACS Chem Neurosci. 2010 Sep 15;1(9):608-26. doi: 10.1021/cn100045q. Epub 2010 Jul 8.
3
Substoichiometric inhibition of Abeta(1-40) aggregation by a tandem Abeta(40-1-Gly8-1-40) peptide.串联的Abeta(40-1-Gly8-1-40)肽对Abeta(1-40)聚集的亚化学计量抑制作用
Biochem Biophys Res Commun. 2010 Jul 2;397(3):509-12. doi: 10.1016/j.bbrc.2010.05.144. Epub 2010 May 31.
4
Aggregation and fibril morphology of the Arctic mutation of Alzheimer's Aβ peptide by CD, TEM, STEM and in situ AFM.通过 CD、TEM、STEM 和原位 AFM 研究阿尔茨海默病 Aβ 肽的北极突变的聚集和原纤维形态。
J Struct Biol. 2012 Oct;180(1):174-89. doi: 10.1016/j.jsb.2012.06.010. Epub 2012 Jun 28.
5
S14G-humanin inhibits Aβ1-42 fibril formation, disaggregates preformed fibrils, and protects against Aβ-induced cytotoxicity in vitro.S14G-人源神经调节素抑制 Aβ1-42 纤维形成,解聚已形成的纤维,并在体外防止 Aβ 诱导的细胞毒性。
J Pept Sci. 2013 Mar;19(3):159-65. doi: 10.1002/psc.2484. Epub 2013 Jan 24.
6
Synthesis and evaluation of ferrocenoyl pentapeptide (Fc-KLVFF) as an inhibitor of Alzheimer's Aβ₁-₄₂ fibril formation in vitro.合成并评价二茂铁酰基五肽(Fc-KLVFF)作为阿尔茨海默病 Aβ₁-₄₂纤维体外形成的抑制剂。
Bioorg Med Chem Lett. 2011 Oct 1;21(19):5818-21. doi: 10.1016/j.bmcl.2011.07.111. Epub 2011 Aug 2.
7
N-terminal domain of myelin basic protein inhibits amyloid beta-protein fibril assembly.髓鞘碱性蛋白的 N 端结构域抑制淀粉样β蛋白纤维的组装。
J Biol Chem. 2010 Nov 12;285(46):35590-8. doi: 10.1074/jbc.M110.169599. Epub 2010 Aug 31.
8
Aβ(39-42) modulates Aβ oligomerization but not fibril formation.Aβ(39-42) 调节 Aβ 寡聚体的形成但不调节纤维的形成。
Biochemistry. 2012 Jan 10;51(1):108-17. doi: 10.1021/bi201520b. Epub 2011 Dec 23.
9
Tabersonine inhibits amyloid fibril formation and cytotoxicity of Aβ(1-42).塔伯宁抑制淀粉样纤维形成和 Aβ(1-42)的细胞毒性。
ACS Chem Neurosci. 2015 Jun 17;6(6):879-88. doi: 10.1021/acschemneuro.5b00015. Epub 2015 Apr 23.
10
Peptide and protein mimetics inhibiting amyloid beta-peptide aggregation.抑制β-淀粉样肽聚集的肽和蛋白质模拟物。
Acc Chem Res. 2008 Oct;41(10):1309-18. doi: 10.1021/ar8000475.

引用本文的文献

1
Effects of chirality and side chain length in C-dialkylated residues on β-hairpin peptide folded structure and stability.手性和侧链长度对 C-二烷基化残基β-发夹肽折叠结构和稳定性的影响。
Org Biomol Chem. 2023 Aug 9;21(31):6320-6324. doi: 10.1039/d3ob00963g.
2
Molecular Mechanisms of Inhibition of Protein Amyloid Fibril Formation: Evidence and Perspectives Based on Kinetic Models.抑制蛋白淀粉样纤维形成的分子机制:基于动力学模型的证据和观点。
Int J Mol Sci. 2022 Nov 3;23(21):13428. doi: 10.3390/ijms232113428.
3
Aβ and Tau Interact with Metal Ions, Lipid Membranes and Peptide-Based Amyloid Inhibitors: Are These Common Features Relevant in Alzheimer's Disease?β淀粉样蛋白和 Tau 与金属离子、脂膜和基于肽的淀粉样蛋白抑制剂相互作用:这些共同特征在阿尔茨海默病中是否相关?
Molecules. 2022 Aug 9;27(16):5066. doi: 10.3390/molecules27165066.
4
Cell-Penetrating Peptides with Unexpected Anti-Amyloid Properties.具有意外抗淀粉样蛋白特性的细胞穿透肽。
Pharmaceutics. 2022 Apr 9;14(4):823. doi: 10.3390/pharmaceutics14040823.
5
Molecular mechanisms of amyloid disaggregation.淀粉样蛋白解聚的分子机制。
J Adv Res. 2021 May 20;36:113-132. doi: 10.1016/j.jare.2021.05.007. eCollection 2022 Feb.
6
Rationally designed peptide-based inhibitor of Aβ42 fibril formation and toxicity: a potential therapeutic strategy for Alzheimer's disease.理性设计的 Aβ42 纤维形成和毒性的肽类抑制剂:阿尔茨海默病的潜在治疗策略。
Biochem J. 2020 Jun 12;477(11):2039-2054. doi: 10.1042/BCJ20200290.
7
Nanomedicine Against Aβ Aggregation by β-Sheet Breaker Peptide Delivery: In Vitro Evidence.通过β-折叠破坏肽递送的纳米医学抗Aβ聚集:体外证据
Pharmaceutics. 2019 Nov 1;11(11):572. doi: 10.3390/pharmaceutics11110572.
8
Thermodynamic and Structural Impact of α,α-Dialkylated Residue Incorporation in a β-Hairpin Peptide.α,α-二取代残基在β-发夹肽中的掺入对其热力学和结构的影响。
Org Lett. 2016 Aug 5;18(15):3902-5. doi: 10.1021/acs.orglett.6b01936. Epub 2016 Jul 20.
9
Fibril Core of Transforming Growth Factor Beta-Induced Protein (TGFBIp) Facilitates Aggregation of Corneal TGFBIp.转化生长因子β诱导蛋白(TGFBIp)的原纤维核心促进角膜TGFBIp的聚集。
Biochemistry. 2015 May 19;54(19):2943-56. doi: 10.1021/acs.biochem.5b00292. Epub 2015 May 6.
10
Polyphenols as therapeutic molecules in Alzheimer's disease through modulating amyloid pathways.多酚作为通过调节淀粉样蛋白途径治疗阿尔茨海默病的治疗分子。
Mol Neurobiol. 2015 Apr;51(2):466-79. doi: 10.1007/s12035-014-8722-9. Epub 2014 May 15.

本文引用的文献

1
Structure-activity relationships in peptide modulators of β-amyloid protein aggregation: variation in α,α-disubstitution results in altered aggregate size and morphology.β-淀粉样蛋白聚集肽调节剂的构效关系:α,α-二取代的变化导致聚集物的大小和形态发生改变。
ACS Chem Neurosci. 2010 Sep 15;1(9):608-26. doi: 10.1021/cn100045q. Epub 2010 Jul 8.
2
High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients.阿尔茨海默病患者脑脊液中高分子量β-淀粉样寡聚物升高。
FASEB J. 2010 Aug;24(8):2716-26. doi: 10.1096/fj.09-150359. Epub 2010 Mar 25.
3
Beta-amyloid protein aggregation.β-淀粉样蛋白聚集
Methods Mol Biol. 2007;386:203-25. doi: 10.1007/1-59745-430-3_7.
4
Contrasting in vivo effects of two peptide-based amyloid-beta protein aggregation inhibitors in a transgenic mouse model of amyloid deposition.两种基于肽的β淀粉样蛋白聚集抑制剂在淀粉样蛋白沉积转基因小鼠模型中的体内效应对比
Cell Transplant. 2008;17(4):397-408.
5
Aggregation of Abeta(1-42) in the presence of short peptides: conformational studies.短肽存在下β-淀粉样蛋白(1-42)的聚集:构象研究
J Pept Sci. 2008 Jun;14(6):731-41. doi: 10.1002/psc.990.
6
Designing peptide inhibitors for oligomerization and toxicity of Alzheimer's beta-amyloid peptide.设计针对阿尔茨海默病β-淀粉样肽寡聚化和毒性的肽抑制剂。
Biochemistry. 2008 Feb 19;47(7):1984-92. doi: 10.1021/bi701415b. Epub 2008 Jan 12.
7
Alzheimer's Abeta peptides containing an isostructural backbone mutation afford distinct aggregate morphologies but analogous cytotoxicity. Evidence for a common low-abundance toxic structure(s)?含有同构主链突变的阿尔茨海默病β淀粉样肽呈现出不同的聚集形态,但细胞毒性类似。是否存在共同的低丰度毒性结构的证据?
Biochemistry. 2008 Jan 8;47(1):50-9. doi: 10.1021/bi701757v. Epub 2007 Dec 14.
8
New insights into the mechanism of Alzheimer amyloid-beta fibrillogenesis inhibition by N-methylated peptides.N-甲基化肽抑制阿尔茨海默病β-淀粉样蛋白纤维形成机制的新见解。
Biophys J. 2007 Nov 1;93(9):3015-25. doi: 10.1529/biophysj.107.112086. Epub 2007 Jul 13.
9
Design and synthesis of chiral alpha,alpha-disubstituted amino acids and conformational study of their oligopeptides.手性α,α-二取代氨基酸的设计与合成及其寡肽的构象研究
Chem Pharm Bull (Tokyo). 2007 Mar;55(3):349-58. doi: 10.1248/cpb.55.349.
10
Role of aggregation conditions in structure, stability, and toxicity of intermediates in the Abeta fibril formation pathway.聚集条件在β-淀粉样蛋白纤维形成途径中中间体的结构、稳定性和毒性方面的作用。
Protein Sci. 2007 Apr;16(4):723-32. doi: 10.1110/ps.062514807. Epub 2007 Feb 27.

β 淀粉样肽末端修饰对β 淀粉样肽纤维形成的影响。

Effects of peptides derived from terminal modifications of the aβ central hydrophobic core on aβ fibrillization.

出版信息

ACS Chem Neurosci. 2010 Oct 20;1(10):661-78. doi: 10.1021/cn900019r. Epub 2010 Aug 26.

DOI:10.1021/cn900019r
PMID:22778807
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3368634/
Abstract

Considerable research effort has focused on the discovery of mitigators that block the toxicity of the β-amyloid peptide (Aβ) by targeting a specific step involved in Aβ fibrillogenesis and subsequent aggregation. Given that aggregation intermediates are hypothesized to be responsible for Aβ toxicity, such compounds could likely prevent or mitigate aggregation, or alternatively cause further association of toxic oligomers into larger nontoxic aggregates. Herein we investigate the effect of modifications of the KLVFF hydrophobic core of Aβ by replacing N- and C-terminal groups with various polar moieties. Several of these terminal modifications were found to disrupt the formation of amyloid fibrils and in some cases induced the disassembly of preformed fibrils. Significantly, mitigators that incorporate MiniPEG polar groups were found to be effective against Aβ(1-40) fibrilligonesis. Previously, we have shown that mitigators incorporating alpha,alpha-disubstituted amino acids (ααAAs) were effective in disrupting fibril formation as well as inducing fibril disassembly. In this work, we further disclose that the number of polar residues (six) and ααAAs (three) in the original mitigator can be reduced without dramatically changing the ability to disrupt Aβ(1-40) fibrillization in vitro.

摘要

大量的研究工作集中在发现通过针对 Aβ 原纤维形成和随后的聚集涉及的特定步骤来阻断β-淀粉样肽(Aβ)毒性的缓解剂。鉴于聚集中间体被假设为负责 Aβ 毒性,这样的化合物可能能够预防或减轻聚集,或者使有毒的低聚物进一步聚集到更大的无毒聚集体中。在此,我们通过用各种极性部分取代 N-和 C-末端来研究 Aβ 的 KLVFF 疏水核心的修饰的效果。发现这些末端修饰中的几种破坏了淀粉样纤维的形成,并且在某些情况下诱导了预形成的纤维的解聚。显著地,发现包含 MiniPEG 极性基团的缓解剂可有效地对抗 Aβ(1-40)原纤维的形成。以前,我们已经表明,包含α,α-二取代氨基酸(ααAAs)的缓解剂在破坏纤维形成以及诱导纤维解聚方面是有效的。在这项工作中,我们进一步揭示,原始缓解剂中的极性残基(六个)和ααAAs(三个)的数量可以减少,而不会显著改变体外破坏 Aβ(1-40)纤维化的能力。